Product & ReviewsAntibodies

ChIPAb+ Acetyl-Histone H3 (Lys27) - ChIP Validated Antibody and Primer Set

Product Details

Cat. No.
17-683
Type
Primary Antibody
Clonality
Monoclonal
Host
Mouse
Merck KGaA, Darmstadt, Germany

The supplier does not provide quotations for this antibody through SelectScience. You can search for similar antibodies in our  Antibody Directory.

Description

All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction. The ChIPAb+ Acetyl-Histone H3 (Lys27) set includes the Anti-acetyl-Histone H3 (Lys27) antibody, a negative control antibody (purified Mouse IgG), and qPCR primers which amplify a 178 bp region within the promoter of the human RPL10 gene. The acetyl-histone H3 (Lys27) and negative control antibodies are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of acetyl-histone H3 (Lys27)-associated chromatin.

Biological Information

  • Clonality: Monoclonal
  • Host: Mouse
  • Reactivity: Human, Vertebrate
  • Isotype: IgG

Handling

  • Storage: Stable for 1 year at -20°C from date of receipt. Aliquot upon thawing, avoid freeze thaw cycles.
  • Specificity: 5

Applications

  • Chromatin Immunoprecipitation (ChIP)
  • Western Blotting (WB)

Average Rating 5.0

|1Scientists have reviewed this product

Specificity rating
Sensitivity rating
Quality rating
Write your own review

Antibody with high quality.

 

Average Rating 5.0

Application Area:

ChIP and ChIP-seq

I always achieve reproducible results for ChIP experiments with this antibody. It is reliable, and easy to use. It contains primer set as negative control and positive control.

Review Date: 4 Dec 2018 | Merck KGaA, Darmstadt, Germany

Product Overview

Links